KIDNEY CANCER
Clinical trials for KIDNEY CANCER explained in plain language.
Never miss a new study
Get alerted when new KIDNEY CANCER trials appear
Sign up with your email to follow new studies for KIDNEY CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Kidney cancer combo trial halted early – what we know
Disease control TerminatedThis study tested two new drug combinations for people with advanced clear cell kidney cancer that had already been treated. The goal was to see if adding the experimental drug NKT2152 to standard therapies could shrink tumors or slow the disease. The trial was stopped early, so …
Matched conditions: KIDNEY CANCER
Phase: PHASE2 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated May 13, 2026 16:01 UTC
-
New cancer drug AUR106 tested in advanced tumors – early results
Disease control TerminatedThis early-stage study tested a new drug called AUR106 in 21 adults with advanced solid tumors like lung, stomach, bladder, kidney, colon, or esophageal cancer that had come back or spread. The main goal was to find the safest dose and understand how the drug works in the body. T…
Matched conditions: KIDNEY CANCER
Phase: PHASE1 • Sponsor: Aurigene Discovery Technologies Limited • Aim: Disease control
Last updated May 11, 2026 20:51 UTC
-
New pill shows promise in halting advanced kidney cancer growth
Disease control TerminatedThis trial tested an oral drug called NKT2152 for people with advanced clear cell kidney cancer that has worsened after other treatments. The drug works by blocking a protein that helps cancer grow. The study aimed to find the safest dose and see if it can shrink tumors or slow t…
Matched conditions: KIDNEY CANCER
Phase: PHASE1, PHASE2 • Sponsor: NiKang Therapeutics, Inc. • Aim: Disease control
Last updated May 07, 2026 18:43 UTC
-
Experimental cancer drug TAK-500 tested in 61 patients
Disease control TerminatedThis study tested a new drug called TAK-500, given alone or with another drug (pembrolizumab), in 61 adults with advanced solid tumors like pancreatic, liver, and lung cancer. The main goals were to check safety and see if the drug could shrink tumors. The study was stopped early…
Matched conditions: KIDNEY CANCER
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Apr 23, 2026 12:45 UTC
-
Memory breathing therapy tested for cancer PTSD – study halted early
Symptom relief TerminatedThis study tested a special technique that combines organizing traumatic memories with slow, deep breathing to reduce PTSD symptoms in people with advanced cancer and their partners. The goal was to see if this approach could lower stress, inflammation, and possibly improve survi…
Matched conditions: KIDNEY CANCER
Phase: PHASE2 • Sponsor: Centre Oscar Lambret • Aim: Symptom relief
Last updated May 14, 2026 12:05 UTC